RxDoctor Payments Data

Theresa Mallick-Searle

Nurse Practitioner · Stanford, CANPI 1841296779

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.2%. 2025 is the largest year on record at $66,109, 3.2 times the $20,520 reported in 2021. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$192,787in general payments, 2019–2025

Across 329 payments — averaging $585.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$35K
  • Averitas Pharma Inc.$28K
  • Vertex$26K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21K
  • Axsome Therapeutics, Inc.$14K
  • GRT US Holding, Inc.$13K
  • plus $56K from 20 others
$7,340in research payments, 2019–2025

Across 3 payments — averaging $2446.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$7K

What the payments were for

  • Consulting fees$42,13322%
  • Speaking & faculty fees$110,33457%
  • Grants$420%
  • Travel & lodging$30,89616%
  • Food & beverage$9,3385%
  • Education$450%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,787 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$41,456
Medicare patients
255
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm11$7,623
Pregabalin15$2,207
Gabapentin34$616
Duloxetine Hcl11$149

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →